Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Möricke, A; Lauten, M; Beier, R; Odenwald, E; Stanulla, M; Zimmermann, M; Attarbaschi, A; Niggli, F; Schrappe, M (2013). Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Klinische Pädiatrie, 225 Supp:S50-S56.

Schmitz, M; Breithaupt, P; Scheidegger, N; Cario, G; Bonapace, L; Meissner, B; Mirkowska, P; Tchinda, J; Niggli, F K; Stanulla, M; Schrappe, M; Schrauder, A; Bornhauser, B C; Bourquin, J P (2011). Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood, 118(7):1854-1864.

Hertzberg, L; Vendramini, E; Ganmore, I; Cazzaniga, G; Schmitz, M; Chalker, J; Shiloh, R; Iacobucci, I; Shochat, C; Zeligson, S; Cario, G; Stanulla, M; Strehl, S; Russell, L J; Harrison, C J; Bornhauser, B; Yoda, A; Rechavi, G; Bercovich, D; Borkhardt, A; Kempski, H; te Kronnie, G; Bourquin, J P; Domany, E; Izraeli, S (2010). Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115(5):1006-1017.

Bonapace, L; Bornhauser, B C; Schmitz, M; Cario, G; Ziegler, Urs; Niggli, F K; Schäfer, B W; Schrappe, M; Stanulla, M; Bourquin, J P (2010). Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 120(4):1310-1323.

Möricke, A; Zimmermann, M; Reiter, A; Henze, G; Schrauder, A; Gadner, H; Ludwig, W D; Ritter, J; Harbott, J; Mann, G; Klingebiel, T; Zintl, F; Niemeyer, C; Kremens, B; Niggli, F; Niethammer, D; Welte, K; Stanulla, M; Odenwald, E; Riehm, H; Schrappe, M (2010). Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia, 24(2):265-284.

Conter, V; Bartram, C R; Valsecchi, M G; Schrauder, A; Panzer-Grümayer, R; Möricke, A; Aricò, M; Zimmermann, M; Mann, G; De Rossi, G; Stanulla, M; Locatelli, F; Basso, G; Niggli, F; Barisone, E; Henze, G; Ludwig, W D; Haas, O A; Cazzaniga, G; Koehler, R; Silvestri, D; Bradtke, J; Parasole, R; Beier, R; van Dongen, J J M; Biondi, A; Schrappe, M (2010). Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 115(16):3206-14.

Teuffel, O; Stanulla, M; Cario, G; Ludwig, W D; Rottgers, S; Schafer, B W; Zimmermann, M; Schrappe, M; Niggli, F K (2008). Anemia and survival in childhood acute lymphoblastic leukemia. Haematologica, 93(11):1652-7.

Flohr, T; Schrauder, A; Cazzaniga, G; Panzer-Grümayer, R; van der Velden, V; Fischer, S; Stanulla, M; Basso, G; Niggli, F K; Schäfer, B W; Sutton, R; Koehler, R; Zimmermann, M; Valsecchi, M G; Gadner, H; Masera, G; Schrappe, M; van Dongen, J J M; Biondi, A; Bartram, C R (2008). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 22(4):771-782.

Bercovich, D; Ganmore, I; Scott, L M; Wainreb, G; Birger, Y; Elimelech, A; Shochat, C; Cazzaniga, G; Biondi, A; Basso, G; Cario, G; Schrappe, M; Stanulla, M; Strehl, S; Haas, O; Mann, G; Binder, V; Borkhardt, A; Kempski, H; Trka, J; Bielorei, B; Avigad, S; Stark, B; Smith, O; Dastugue, N; Bourquin, J-P; Tal, N B; Green, A R; Izraeli, S (2008). Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 372(9648):1484-1492.

Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 111(9):4477-4489.

This list was generated on Wed Oct 18 09:53:46 2017 CEST.